Literature DB >> 16567409

Variation in the divalent cation requirements of influenza A virus N1 neuraminidases.

Ian C Brett1, Bert E Johansson.   

Abstract

Enzymatic kinetic parameters of influenza A virus N1 neuraminidases (NA) chromatographically purified from several vaccine candidate strains were tested. With ionic strength held constant, Ca2+ or Mg2+ increased the initial rate of enzymatic activity. The 1934 and 1943 strains had statistically significant highest initial velocities, V(max)/K(m) and V(max). There were no significant differences among the influenza virus strains from 1947 to 1991. Measured K(m) for the 1943 strain (6.2 x 10(-5) M) was significantly higher than other strains (3.1-4.7 x 10(-5) M). V(max)/K(m) varied from 0.78 M(-1) s(-1) to 0.91 M(-1) s(-1) and V(max) varied from 3.0 s(-1) to 5.5 s(-1) before the addition of a divalent cation and increased approximately 2-fold for each of these kinetic parameters for each strain after the addition of exogenous Ca2+ or Mg2+. Dialysis reduced the initial velocity and immunogenicity of each strain with significant differences found among strains. Enzymatic activity and immunogenicity were partially restored by the addition of exogenous Ca2+. Nucleic acid sequence analysis could not predict these differences. Selection of vaccine strains must include analysis of antigenic changes, but also enzymatic studies and determination of the requirement of divalent cations to maintain immunogenicity and activity during production.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16567409     DOI: 10.1093/jb/mvj051

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  7 in total

1.  Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.

Authors:  Judith D Easterbrook; Louis M Schwartzman; Jin Gao; John C Kash; David M Morens; Laura Couzens; Hongquan Wan; Maryna C Eichelberger; Jeffery K Taubenberger
Journal:  Virology       Date:  2012-06-22       Impact factor: 3.616

Review 2.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

3.  Combining crystallographic information and an aspherical-atom data bank in the evaluation of the electrostatic interaction energy in an enzyme-substrate complex: influenza neuraminidase inhibition.

Authors:  Paulina M Dominiak; Anatoliy Volkov; Adam P Dominiak; Katarzyna N Jarzembska; Philip Coppens
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-04-18

4.  Amino acid determinants conferring stable sialidase activity at low pH for H5N1 influenza A virus neuraminidase.

Authors:  Tadanobu Takahashi; Chairul A Nidom; Mai Thi Quynh Le; Takashi Suzuki; Yoshihiro Kawaoka
Journal:  FEBS Open Bio       Date:  2012-09-05       Impact factor: 2.693

5.  The effect of calcium and magnesium on activity, immunogenicity, and efficacy of a recombinant N1/N2 neuraminidase vaccine.

Authors:  Luca T Giurgea; Jae-Keun Park; Kathie-Anne Walters; Kelsey Scherler; Adriana Cervantes-Medina; Ashley Freeman; Luz Angela Rosas; John C Kash; Jeffery K Taubenberger; Matthew J Memoli
Journal:  NPJ Vaccines       Date:  2021-04-06       Impact factor: 7.344

6.  Mutations in NA that induced low pH-stability and enhanced the replication of pandemic (H1N1) 2009 influenza A virus at an early stage of the pandemic.

Authors:  Tadanobu Takahashi; Jiasheng Song; Takashi Suzuki; Yoshihiro Kawaoka
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

7.  Protective efficacy of anti-neuraminidase monoclonal antibodies against H7N9 influenza virus infection.

Authors:  Fei-Fei Xiong; Xue-Ying Liu; Fei-Xia Gao; Jian Luo; Peng Duan; Wen-Song Tan; Ze Chen
Journal:  Emerg Microbes Infect       Date:  2020-01-02       Impact factor: 7.163

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.